Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
Colonoscopy Reduces Risk of Death from Colorectal Cancer in High-Risk Patients
(Posted: 03/19/2012) - Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half. The findings appeared February 23, 2012, in the New England Journal of Medicine.
Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
(Posted: 07/19/2011, Updated: 03/07/2012) - Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.
Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 02/17/2012) - Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination (DRE).
Genetic Abnormality Predicts Treatment Benefit for Patients with Rare Brain Tumor
(Posted: 02/09/2012) - The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
(Posted: 03/19/2012) - Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half. The findings appeared February 23, 2012, in the New England Journal of Medicine.
Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
(Posted: 07/19/2011, Updated: 03/07/2012) - Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.
Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 02/17/2012) - Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination (DRE).
Genetic Abnormality Predicts Treatment Benefit for Patients with Rare Brain Tumor
(Posted: 02/09/2012) - The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
